Eric Bednarski
Director/Board Member at OPTINOSE, INC.
Net worth: - $ as of 2024-04-29
Profile
Dr. Eric Bednarski is an Independent Director at OptiNose, Inc., a Partner at MVM Partners LLC and a Chairman at Tarsa Therapeutics, Inc. He is on the Board of Directors at OptiNose, Inc., MDxHealth SA, Biotheranostics, Inc. and Neurolens, Inc. Dr. Bednarski was previously employed as a Co-Founder by Ampla Pharmaceuticals, Inc., a Principal by Advent International Corp, a Principal by DuPont Merck Pharmaceutical Co., a Non-Executive Director by Nxera Pharma UK Ltd., a Director-Corporate Finance Group by Silicon Valley Bank, a Principal by SVB Asset Management, and a Partner by Synthesis Capital.
He also served on the board at Prexa Pharmaceuticals, Inc., AccuVein, Inc. and SOLX, Inc. He received his undergraduate degree from Brown University and a doctorate degree from the University of California.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
OPTINOSE, INC.
-.--% | 2023-06-07 | 0 ( -.--% ) | - $ | 2024-04-29 |
Eric Bednarski active positions
| Companies | Position | Start |
|---|---|---|
| MDXHEALTH SA | Director/Board Member | 2020-07-29 |
| OPTINOSE, INC. | Director/Board Member | 2021-12-09 |
| MVM Partners LLC | Private Equity Investor | 2007-12-31 |
Biotheranostics, Inc.
 Biotheranostics, Inc. Medical/Nursing ServicesHealth Services Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA. | Director/Board Member | - |
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | Chairman | 2009-10-20 |
Neurolens, Inc.
 Neurolens, Inc. Electronic ComponentsElectronic Technology Neurolens, Inc. is a company that commercializes breakthrough technology to improve vision care. The company's patented contoured prism technology provides visual comfort for the nearly 65% of US adults who complain of headaches, neck/shoulder pain, and eyestrain when using digital devices, reading, or doing detail work. The company is based in Coppell, TX. Inspired by a breakthrough discovery linking optometry and neurology, Neurolens is unlocking a new dimension of vision care. The Neurolens contoured prism design helps the eyes work together comfortably, bringing the eyes into alignment to relieve painful symptoms. The technology is only available to independent eye care providers. The company was founded in 2012 by Davis Corley, and Pierre Bertrand has been the CEO of the company since 2019. | Director/Board Member | - |
Former positions of Eric Bednarski
| Companies | Position | End |
|---|---|---|
Advent International LP
 Advent International LP Investment ManagersFinance Advent International LP (Advent) is an independent private equity firm founded in 1984 by Henry H. Haight. The firm is headquartered in Boston, Massachusetts. | Private Equity Analyst | 2007-04-30 |
SVB Asset Management
 SVB Asset Management Investment ManagersFinance SVB Asset Management is a SEC-registered investment advisor headquartered in San Francisco, California. The firm was founded in 2002 and is a wholly-owned subsidiary of First-Citizens Bank & Trust Co., which in turn, is a wholly owned subsidiary of First Citizens BancShares, Inc. (NASDAQ: FCNCA). SVB Asset Management provides discretionary investment management services for corporate clients in the innovation economy, specifically in the technology and life science/healthcare industries. | Corporate Officer/Principal | 2000-12-30 |
Prexa Pharmaceuticals, Inc.
 Prexa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prexa Pharmaceuticals, Inc. developed oral small molecule monoamine reuptake inhibitors that act potently at the dopamine transporter. It engaged in developing small molecules designed to enhance the action of the neurotransmitter dopamine, potentially providing new alternatives to treating CNS diseases and disorders such as ADHD, depression, and Parkinson's disease. The company was founded in 2006 and was headquartered in Boston, MA. | Founder | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Eric Bednarski
| Brown University | Undergraduate Degree |
| University of California | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MDXHEALTH SA | Health Technology |
| OPTINOSE, INC. | Health Technology |
| Private companies | 14 |
|---|---|
Advent International LP
Advent International LP Investment ManagersFinance Advent International LP (Advent) is an independent private equity firm founded in 1984 by Henry H. Haight. The firm is headquartered in Boston, Massachusetts. | Finance |
Biotheranostics, Inc.
Biotheranostics, Inc. Medical/Nursing ServicesHealth Services Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA. | Health Services |
Ampla Pharmaceuticals, Inc.
 Ampla Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ampla Pharmaceuticals, Inc. engages in the drug discovery of novel oral small molecule drugs for treatment of diabetes and metabolism disorders. It also designs and develops biopharmaceutical drugs. The company was founded by James R. Hauske and Eric Bednarski in 2006 and is headquartered in La Jolla, CA. | Health Technology |
Prexa Pharmaceuticals, Inc.
Prexa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prexa Pharmaceuticals, Inc. developed oral small molecule monoamine reuptake inhibitors that act potently at the dopamine transporter. It engaged in developing small molecules designed to enhance the action of the neurotransmitter dopamine, potentially providing new alternatives to treating CNS diseases and disorders such as ADHD, depression, and Parkinson's disease. The company was founded in 2006 and was headquartered in Boston, MA. | Health Technology |
SVB Asset Management
SVB Asset Management Investment ManagersFinance SVB Asset Management is a SEC-registered investment advisor headquartered in San Francisco, California. The firm was founded in 2002 and is a wholly-owned subsidiary of First-Citizens Bank & Trust Co., which in turn, is a wholly owned subsidiary of First Citizens BancShares, Inc. (NASDAQ: FCNCA). SVB Asset Management provides discretionary investment management services for corporate clients in the innovation economy, specifically in the technology and life science/healthcare industries. | Finance |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
SOLX, Inc.
 SOLX, Inc. Medical SpecialtiesHealth Technology SOLX, Inc. specializes in management and surgical treatment of glaucoma. It offers Gold Shunt is a novel, minimally invasive device that advances the surgical treatment of glaucoma. The company was founded by Doug P. Adams in 2000 and is headquartered in Waltham, MA. | Health Technology |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |
Silicon Valley Bank
 Silicon Valley Bank Regional BanksFinance Silicon Valley Bank provides commercial banking services. It offers banking services to the hardware and infrastructure, software and internet, life science and healthcare, energy and resource innovation, private equity and venture capital, and premium wine industries. The company was founded in 1983 and is headquartered in Santa Clara, CA. | Finance |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | Health Technology |
AccuVein, Inc.
 AccuVein, Inc. Medical SpecialtiesHealth Technology AccuVein, Inc. provides medical imaging solutions. Its products include vein viewing system, extended reach powered wheel stand, unpowered wheel stand, and hands free solution. The company was founded by Ron P. Goldman on September 7, 2011 and is headquartered in Medford, NY. | Health Technology |
Synthesis Capital
 Synthesis Capital Investment ManagersFinance Synthesis Capital is a venture capital firm founded in 2007. The firm is headquartered in Boston, Massachusetts. | Finance |
| MVM Partners LLC | Finance |
Neurolens, Inc.
Neurolens, Inc. Electronic ComponentsElectronic Technology Neurolens, Inc. is a company that commercializes breakthrough technology to improve vision care. The company's patented contoured prism technology provides visual comfort for the nearly 65% of US adults who complain of headaches, neck/shoulder pain, and eyestrain when using digital devices, reading, or doing detail work. The company is based in Coppell, TX. Inspired by a breakthrough discovery linking optometry and neurology, Neurolens is unlocking a new dimension of vision care. The Neurolens contoured prism design helps the eyes work together comfortably, bringing the eyes into alignment to relieve painful symptoms. The technology is only available to independent eye care providers. The company was founded in 2012 by Davis Corley, and Pierre Bertrand has been the CEO of the company since 2019. | Electronic Technology |
- Stock Market
- Insiders
- Eric Bednarski
